Agenda for Pre-Conference Half-Day - Monday November 16, 2026 - EST
Escalating rebates for formulary access, restrictive PBM measures to limit utilization and the Inflation Reduction has a profound impact on market access and GTN.
This course is designed to enhance your knowledge of PBM market access restrictions, escalating rebate & pricing pressures, contracting challenges and the Inflation Reduction Act. Numerical examples will be presented illustrating key concepts and practical applications.
By attending this course, you'll learn about:
- Pharmaceutical ecosystem – PBMs, pharma companies, payers, GPOs, pharmacies insurers and patients
- Unique dynamics of PBM expansion, consolidation and vertical integration
- PBM revenue sources
- Why PBMs prefer high-price drugs with high rebates
- New PBM regulations
- Impact of PBM formulary exclusions, prior authorization, and step edits
- Key factors impacting rebate rates and formulary position
- Implications of escalating patient out-of-pocket costs
- Copay and patient assistance programs
- Charitable foundations
- Specialty carveout/alternative funding programs
- Unprofitable prescriptions
- Optimizing market access – developing a compelling value proposition
- Rebate walls and biosimilar market access challenges
- Value-based, installment-based, indication-based and Netflix contracts
- ROI of PBM contracting scenarios and sensitivity analysis
- Rebate walls
- Inflation Reduction Act:
- Medicare Price Negotiation
- Process, provisions, and drug selection criteria
- Spillover to drugs not subject to price negotiation, Medicaid & 340B
- Inflation Rebates
- Double whammy (inflation & price protection rebates)
- Reduction of patient out-of-pocket costs
- Benefit Design
- Impact on GTN and market access
- Implications of catastrophic discounts for drugs not selected for Maximum Fair Price
- Medicare Price Negotiation
*Additional fee to participate
- Murray Kay - Former Senior Vice President and Chief Financial Officer, Solvay Pharmaceuticals and Former Commercial Controller, AbbVie
- Master the fundamentals of gross-to-net calculations and key components that impact revenue recognition
- Learn industry best practices for managing rebates, chargebacks, discounts, and other deductions
- Gain practical skills to navigate complex GTN scenarios and improve forecasting accuracy
- Build confidence in communicating GTN metrics and insights to stakeholders across your organization
- Robert Lucchesi - Director, GTN Forecasting, Novo Nordisk
Engage in dynamic and collaborative Hot Topic Roundtable discussions where industry leaders come together to address the most critical issues and evolving GTN developments shaping the life sciences sector.
This interactive session provides attendees with an exceptional chance to:
- Participate in substantive conversations with colleagues and subject matter experts
- Discover creative approaches to multifaceted industry obstacles
- Connect with peers navigating comparable challenges and possibilities
Whether your goal is to share your knowledge, discover new perspectives or build relationships with fellow professionals, this roundtable delivers an ideal platform for thought-provoking discussion and collaborative learning.
- Jennifer Sharpe - Vice President, Gross-to-Net Consulting and Facilitator, Revenue Analytics Collaborative, IntegriChain
